药物耐药性患者的替代周边测试
Monika Thakur1,2, Abhinay Kumar Gattu3,4, Jagarlapudi M K Murthy3,4
1Brien Holden Institute of Optometry and Vision Science, Hyderabad Eye Research Foundation, L V Prasad Eye Institute, Hyderabad, India.
PloS one
|February 24, 2025
概括
当标准方法失败时,替代视野测试,如婴儿视觉查器 (BaViS) 和触屏周边测试,对于耐药患者是有效的. 这些方法有助于评估视野缺陷患者的手术适用性.
科学领域:
- 神经学 神经学
- 眼科医生 眼科 眼科
- 医疗器械 医疗器械
背景情况:
- 视野评估对于药物耐药性 (DRE) 的术前评估至关重要,特别是对于后皮层.
- 传统的周边测量,如汉弗里视野分析仪 (HFA),可能不适用于所有DRE患者.
- 探索替代视野评估方法是必要的,以确保全面的手术前评估.
研究的目的:
- 评估在DRE患者中使用替代视野评估方法的可行性和有效性.
- 为了比较触角屏周长度和婴儿视觉选器 (BaViS) 与常规周长度 (HFA) 的可测试性.
- 确定这些替代方法是否可以可靠地量化视野缺陷,以评估外科候选人.
主要方法:
- 对17名DRE患者 (平均年龄18.7岁) 的回顾性研究.
- 不同的检查员试图使用HFA,触屏周长度和/或BaViS来测试视野.
- 使用替代方法的动态周边测量和HFA的动态/静态周边测量来测量视野范围.
主要成果:
- 只有12%的患者能够完成HFA测试.
- 替代方法的测试率很高:BaViS (91%) 和触屏周长度 (87%).
- 在用多种方法测试的患者中获得了可比的视野同视镜;即使量化失败时,BaViS也允许粗略评估.
结论:
- 婴儿视觉查器 (BaViS) 和触角屏周边测量是对DRE患者视野评估的可行的替代方案,当HFA不可行时.
- 这些替代方法可以帮助量化视野缺陷,帮助临床医生评估DRE患者适合手术.
- 这些测试的成功实施可以改善视野缺陷的DRE患者的术前规划.
相关概念视频
Arteries of the Lower Limbs
176
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
176
Antiepileptic Drugs: Glutamate Antagonists
270
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
270
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
Antiepileptic Drugs: Sodium Channel Blockers
350
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
350
Antiepileptic Drugs: GABAergic Pathway Potentiators
309
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
309
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140


